Literature DB >> 29185848

Monoclonal antibodies targeting the disintegrin-like domain of ADAMDEC1 modulates the proteolytic activity and enables quantification of ADAMDEC1 protein in human plasma.

Jacob Lund1,2, Anne Mette Elimar Bitsch1,2, Morten Grønbech Rasch3, Mari Enoksson1, Linda Troeberg4, Hideaki Nagase4, Mette Loftager5, Michael Toft Overgaard2, Helle Heibroch Petersen1.   

Abstract

Decysin-1 (ADAMDEC1) is an orphan ADAM-like metalloprotease with unknown biological function and a short domain structure. ADAMDEC1 mRNA has previously been demonstrated primarily in macrophages and mature dendritic cells. Here, we generated monoclonal antibodies (mAbs) against the mature ADAMDEC1 protein, as well as mAbs specific for the ADAMDEC1 pro-form, enabling further investigations of the metalloprotease. The generated mAbs bind ADAMDEC1 with varying affinity and represent at least six different epitope bins. Binding of mAbs to one epitope bin in the C-terminal disintegrin-like domain efficiently reduces the proteolytic activity of ADAMDEC1. A unique mAb, also recognizing the disintegrin-like domain, stimulates the caseinolytic activity of ADAMDEC1 while having no significant effect on the proteolysis of carboxymethylated transferrin. Using two different mAbs binding the disintegrin-like domain, we developed a robust, quantitative sandwich ELISA and demonstrate secretion of mature ADAMDEC1 protein by primary human macrophages. Surprisingly, we also found ADAMDEC1 present in human plasma with an approximate concentration of 0.5 nM. The presence of ADAMDEC1 both in human plasma and in macrophage cell culture supernatant were biochemically validated using immunoprecipitation and Western blot analysis demonstrating that ADAMDEC1 is secreted in a mature form.

Entities:  

Keywords:  ADAMDEC1; ELISA; Metalloprotease; disintegrin; plasma; quantification

Mesh:

Substances:

Year:  2017        PMID: 29185848      PMCID: PMC5800386          DOI: 10.1080/19420862.2017.1395541

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  26 in total

1.  Expression and inhibition of ADAMDEC1 in craniopharyngioma cells.

Authors:  Jianguo Xu; Liang Liu; Xiaomei Zheng; Chao You; Qiang Li
Journal:  Neurol Res       Date:  2012-07-05       Impact factor: 2.448

2.  Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains.

Authors:  Stefan Gerhardt; Giles Hassall; Paul Hawtin; Eileen McCall; Liz Flavell; Claire Minshull; David Hargreaves; Attilla Ting; Richard A Pauptit; Andrew E Parker; W Mark Abbott
Journal:  J Mol Biol       Date:  2007-08-02       Impact factor: 5.469

3.  Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.

Authors:  Tao Liu; Wei-Jun Qian; Marina A Gritsenko; David G Camp; Matthew E Monroe; Ronald J Moore; Richard D Smith
Journal:  J Proteome Res       Date:  2005 Nov-Dec       Impact factor: 4.466

4.  The ADAMDEC1 (decysin) gene structure: evolution by duplication in a metalloprotease gene cluster on chromosome 8p12.

Authors:  Elizabeth E M Bates; Wolf H Fridman; Chris G F Mueller
Journal:  Immunogenetics       Date:  2002-03-16       Impact factor: 2.846

5.  The soluble protease ADAMDEC1 released from activated platelets hydrolyzes platelet membrane pro-epidermal growth factor (EGF) to active high-molecular-weight EGF.

Authors:  Rui Chen; Ge Jin; Thomas M McIntyre
Journal:  J Biol Chem       Date:  2017-04-28       Impact factor: 5.157

6.  A gene expression profile related to immune dampening in the tumor microenvironment is associated with poor prognosis in gastric adenocarcinoma.

Authors:  Fatima Solange Pasini; Bruno Zilberstein; Igor Snitcovsky; Rosimeire Aparecida Roela; Flavia R Rotea Mangone; Ulysses Ribeiro; Suely Nonogaki; Glauber Costa Brito; Giovanna D Callegari; Ivan Cecconello; Venancio Avancini Ferreira Alves; José Eluf-Neto; Roger Chammas; Miriam Hatsue Honda Federico
Journal:  J Gastroenterol       Date:  2013-11-12       Impact factor: 7.527

7.  Characterization of intestinal inflammation and identification of related gene expression changes in mdr1a(-/-) mice.

Authors:  Y E M Dommels; C A Butts; S Zhu; M Davy; S Martell; D Hedderley; M P G Barnett; W C McNabb; N C Roy
Journal:  Genes Nutr       Date:  2007-09-27       Impact factor: 5.523

8.  Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity.

Authors:  M Roghani; J D Becherer; M L Moss; R E Atherton; H Erdjument-Bromage; J Arribas; R K Blackburn; G Weskamp; P Tempst; C P Blobel
Journal:  J Biol Chem       Date:  1999-02-05       Impact factor: 5.157

9.  Polymerase chain reaction selects a novel disintegrin proteinase from CD40-activated germinal center dendritic cells.

Authors:  C G Mueller; M C Rissoan; B Salinas; S Ait-Yahia; O Ravel; J M Bridon; F Briere; S Lebecque; Y J Liu
Journal:  J Exp Med       Date:  1997-08-29       Impact factor: 14.307

10.  Inflammation, adenoma and cancer: objective classification of colon biopsy specimens with gene expression signature.

Authors:  Orsolya Galamb; Balázs Györffy; Ferenc Sipos; Sándor Spisák; Anna Mária Németh; Pál Miheller; Zsolt Tulassay; Elek Dinya; Béla Molnár
Journal:  Dis Markers       Date:  2008       Impact factor: 3.434

View more
  4 in total

1.  Metalloendopeptidase ADAM-like Decysin 1 (ADAMDEC1) in Colonic Subepithelial PDGFRα+ Cells Is a New Marker for Inflammatory Bowel Disease.

Authors:  Se Eun Ha; Brian G Jorgensen; Lai Wei; Byungchang Jin; Min-Seob Kim; Sandra M Poudrier; Rajan Singh; Allison Bartlett; Hannah Zogg; Sei Kim; Gain Baek; Masaaki Kurahashi; Moon-Young Lee; Yong-Sung Kim; Suck-Chei Choi; Kent C Sasse; Samuel J S Rubin; Andres Gottfried-Blackmore; Laren Becker; Aida Habtezion; Kenton M Sanders; Seungil Ro
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

2.  ADAM-like Decysin-1 (ADAMDEC1) is a positive regulator of Epithelial Defense Against Cancer (EDAC) that promotes apical extrusion of RasV12-transformed cells.

Authors:  Yuta Yako; Takashi Hayashi; Yasuto Takeuchi; Kojiro Ishibashi; Nobuhiro Kasai; Nanami Sato; Keisuke Kuromiya; Susumu Ishikawa; Yasuyuki Fujita
Journal:  Sci Rep       Date:  2018-06-25       Impact factor: 4.379

3.  Upregulation of ADAMDEC1 correlates with tumor progression and predicts poor prognosis in non-small cell lung cancer (NSCLC) via the PI3K/AKT pathway.

Authors:  Weiliang Zhu; Lin Shi; Yuxin Gong; Lin Zhuo; Siyun Wang; Shaobing Chen; Bei Zhang; Bin Ke
Journal:  Thorac Cancer       Date:  2022-02-17       Impact factor: 3.500

Review 4.  Monoclonal antibodies against metzincin targets.

Authors:  Salvatore Santamaria; Rens de Groot
Journal:  Br J Pharmacol       Date:  2018-04-02       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.